British drugmaker GlaxoSmithKline ($GSK) says it is ready to begin clinical trials on an Ebola vaccine later this year and could have the vaccine available by 2015. Glaxo scooped up the vaccine last year in a $325 million buyout of Okairos. The latest outbreak of Ebola, which causes severe hemorrhagic fever, has caused 1,779 infections and 961 deaths, according to the most recent update from the World Health Organization. More